ATE521366T1 - Anwendung von amatoxin-konjugaten und phallotoxin-konjugaten mit makromolekülen zur krebstherapie und therapie von entzündungen - Google Patents
Anwendung von amatoxin-konjugaten und phallotoxin-konjugaten mit makromolekülen zur krebstherapie und therapie von entzündungenInfo
- Publication number
- ATE521366T1 ATE521366T1 AT06010902T AT06010902T ATE521366T1 AT E521366 T1 ATE521366 T1 AT E521366T1 AT 06010902 T AT06010902 T AT 06010902T AT 06010902 T AT06010902 T AT 06010902T AT E521366 T1 ATE521366 T1 AT E521366T1
- Authority
- AT
- Austria
- Prior art keywords
- conjugates
- therapy
- inflammation
- macromolecles
- phallotoxin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06010902A EP1859811B1 (de) | 2006-05-27 | 2006-05-27 | Anwendung von Amatoxin-Konjugaten und Phallotoxin-Konjugaten mit Makromolekülen zur Krebstherapie und Therapie von Entzündungen |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE521366T1 true ATE521366T1 (de) | 2011-09-15 |
Family
ID=37081660
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06010902T ATE521366T1 (de) | 2006-05-27 | 2006-05-27 | Anwendung von amatoxin-konjugaten und phallotoxin-konjugaten mit makromolekülen zur krebstherapie und therapie von entzündungen |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1859811B1 (de) |
AT (1) | ATE521366T1 (de) |
ES (1) | ES2371085T3 (de) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT3192529T (lt) | 2009-04-08 | 2020-06-25 | Faulstich, Heinz, Dr. | Amatoksinu užtaisyti terapiniai su ląstelės paviršiumi susirišantys komponentai, sukonstruoti navikų terapijai |
AU2014208301A1 (en) * | 2009-04-08 | 2014-08-21 | Deutsches Krebsforschungszentrum | Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy |
KR20110140124A (ko) * | 2009-04-08 | 2011-12-30 | 하인즈 파울스티히 | 암치료용 아미톡신-활성 표적 결합 부위 |
EP2436398B1 (de) * | 2010-09-30 | 2013-01-23 | Heidelberg Pharma GmbH | Amatoxinkonjugate mit verbesserten Linkern |
EP2497499A1 (de) * | 2011-03-10 | 2012-09-12 | Heidelberg Pharma GmbH | Amatoxinkonjugate mit verbesserten Verknüpfungen |
US9717803B2 (en) | 2011-12-23 | 2017-08-01 | Innate Pharma | Enzymatic conjugation of polypeptides |
WO2014009426A2 (en) | 2012-07-13 | 2014-01-16 | Innate Pharma | Screening of conjugated antibodies |
EP2684865A1 (de) | 2012-07-13 | 2014-01-15 | Heidelberg Pharma GmbH | Verfahren zum Synthetisieren eines Amatoxinbausteins und von Amatoxinen |
WO2014072482A1 (en) | 2012-11-09 | 2014-05-15 | Innate Pharma | Recognition tags for tgase-mediated conjugation |
EP2774624A1 (de) | 2013-03-04 | 2014-09-10 | Heidelberg Pharma GmbH | Amatoxinderivate |
US10611824B2 (en) | 2013-03-15 | 2020-04-07 | Innate Pharma | Solid phase TGase-mediated conjugation of antibodies |
WO2014202773A1 (en) | 2013-06-20 | 2014-12-24 | Innate Pharma | Enzymatic conjugation of polypeptides |
WO2014202775A1 (en) | 2013-06-21 | 2014-12-24 | Innate Pharma | Enzymatic conjugation of polypeptides |
US9938323B2 (en) | 2014-11-06 | 2018-04-10 | Novartis Ag | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase |
EP3268047B9 (de) | 2015-03-09 | 2024-01-10 | Heidelberg Pharma Research GmbH | Amatoxin-antikörper konjugate |
US10723766B2 (en) | 2015-11-27 | 2020-07-28 | Heidelberg Pharma Research Gmbh | Derivatives of gamma-amanitin |
EP3222292A1 (de) * | 2016-03-03 | 2017-09-27 | Heidelberg Pharma GmbH | Amanitinkonjugate |
EP3452492A1 (de) | 2016-05-05 | 2019-03-13 | Novartis AG | Amatoxinderivate und konjugate davon als inhibitoren der rna-polymerase |
US20190328901A1 (en) | 2016-06-17 | 2019-10-31 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cells |
SG11201811290VA (en) | 2016-06-17 | 2019-01-30 | Magenta Therapeutics Inc | Compositions and methods for the depletion of cd117+cells |
WO2018115466A1 (en) * | 2016-12-23 | 2018-06-28 | Heidelberg Pharma Research Gmbh | Amanitin antibody conjugates |
SG10202102897PA (en) | 2017-01-20 | 2021-04-29 | Magenta Therapeutics Inc | Compositions and methods for the depletion of cd137+ cells |
AU2018314668B2 (en) | 2017-08-07 | 2022-06-02 | Heidelberg Pharma Research Gmbh | Novel method for synthesizing amanitins |
EP3661938A1 (de) | 2017-08-07 | 2020-06-10 | Heidelberg Pharma Research GmbH | Neuartiges verfahren zur synthese von amanitinen |
ES2943335T3 (es) | 2017-09-22 | 2023-06-12 | Heidelberg Pharma Res Gmbh | Conjugados de amanitina dirigidos a PSMA |
JP7280254B2 (ja) | 2017-10-24 | 2023-05-23 | マジェンタ セラピューティクス インコーポレイテッド | Cd117+細胞を減少させるための組成物及び方法 |
AU2018354189A1 (en) | 2017-10-24 | 2020-04-23 | Crispr Therapeutics Ag | Compositions and methods for the depletion of CD117+ cells |
WO2019092148A1 (en) | 2017-11-10 | 2019-05-16 | Innate Pharma | Antibodies with functionalized glutamine residues |
CN110170057A (zh) * | 2019-04-08 | 2019-08-27 | 嘉兴市第二医院 | 一种Tf修饰的负载双药的纳米颗粒制备方法及其应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4925648A (en) * | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
AU5186090A (en) * | 1989-02-23 | 1990-09-26 | Colorado State University Research Foundation | Gnrh analogs for destroying gonadotrophs |
DE19514088A1 (de) * | 1995-04-13 | 1996-10-17 | Deutsches Krebsforsch | Konjugat zur Behandlung von Entzünduns-, Infektions- und/oder Hauterkrankungen |
BR122019027966B8 (pt) * | 2002-05-02 | 2021-07-27 | Wyeth Corp | conjugado monomérico de derivado de caliqueamicina/anti-corpo anti-cd22 e uso dos mesmos |
BR0215935A (pt) * | 2002-11-06 | 2005-08-09 | Wyeth Corp | Terapia combinada para tratamento de leucemia aguda e sìndrome mielodisplásica |
-
2006
- 2006-05-27 EP EP06010902A patent/EP1859811B1/de not_active Not-in-force
- 2006-05-27 ES ES06010902T patent/ES2371085T3/es active Active
- 2006-05-27 AT AT06010902T patent/ATE521366T1/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP1859811B1 (de) | 2011-08-24 |
ES2371085T3 (es) | 2011-12-27 |
EP1859811A1 (de) | 2007-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE521366T1 (de) | Anwendung von amatoxin-konjugaten und phallotoxin-konjugaten mit makromolekülen zur krebstherapie und therapie von entzündungen | |
CY1124166T1 (el) | Συζευγματα αντισωματος φαρμακου (adc) τα οποια δεσμευονται σε 191p4d12 πρωτεϊνες | |
ATE472338T1 (de) | Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs | |
DE602006016344D1 (de) | Für das fibroblastenaktivierungsprotein spezifische antikörpermoleküle und immunkonjugate, die diese enthalten | |
NO20083891L (no) | Anti-5T4 antistoffer og anvendelser derav | |
AR069903A1 (es) | Conjugado anticuerpo- molecula asociada dirigidos a la proteina tirosina quinasa 7 (ptk 7), composicion farmaceutica que lo comprende, acido nucleico, factor de expresion y celula huesped relacionados y su uso para preparar un medicamento util para el tratamiento o prevencion de cancer | |
DE602004025101D1 (de) | Humane anti-humane cd3-bindungsmoleküle | |
CY1118369T1 (el) | Αντισωματα εναντι cd38 για την θεραπεια πολλαπλου μυελωματος | |
EA200900040A1 (ru) | Молекулы антител, которые связываются с человеческим il-17 | |
CY1110783T1 (el) | Μονοκλωνικα αντισωματα κατα αυξητικου παραγοντα ηπατοκυτταρων | |
ATE414106T1 (de) | Pegylierte single-domain-antikörper (dab) | |
CY1115147T1 (el) | Εξουδετερωτικα αντισωματα που εχουν ειδικοτητα για ανθρωπινη il-17 | |
UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
CO6630164A2 (es) | Proteinas que se unen al tnf-a | |
AR069747A1 (es) | Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion | |
AR035977A1 (es) | Inmunoconjugados de anticuerpos cd44 citotoxicos. | |
EA201300016A1 (ru) | Конъюгаты антител человека против тканевого фактора с лекарственными препаратами | |
CR8444A (es) | Immunogenic peptide carrier conjugates and methods of producing same | |
MY158560A (en) | Composition comprising antiboby that binds to domain ii of her2 and acidic variants thereof | |
DE60321041D1 (de) | Antikörper gegen krebsantigen tmeff2 und seine anwendungen | |
ATE442861T1 (de) | Gegen antikörper gerichtete photodynamische therapie | |
PE20090426A1 (es) | Composicion vacunal homogenea para el tratamiento del cancer y su metodo de obtencion | |
UY27291A1 (es) | Inmunoconjugados de anticuerpos cd44 citotóxicos | |
CY1115868T1 (el) | Μορια αντισωματων που εχουν ειδικο χαρακτηρα για το ανθρωπινο il-6 | |
TH160954A (th) | แอนติบอดีดรักคอนจูเกต (adc) ที่จับกับโปรตีน 191p4d12 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |